Biotech · Private company
Molecular Partners AG
Track this companyFree. Adds Molecular Partners AG to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- [203Pb]Pb-MP0712Phase 2 · Large Cell Neuroendocrine CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- [212Pb]Pb-MP0712Phase 2 · Large Cell Neuroendocrine CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- MP0250 DARPin® drug candidate, OsimertinibPhase 1 · EGFR-mutated NSCLC (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsPHASE1_PHASE2 · RECRUITING · started May 18, 2026ClinicalTrials.gov NCT07278479 · fetched Nov 12, 2026
- A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19PHASE2_PHASE3 · TERMINATED · started May 10, 2021ClinicalTrials.gov NCT04828161 · fetched Nov 12, 2026
- MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLCPHASE1 · TERMINATED · started Mar 22, 2018ClinicalTrials.gov NCT03418532 · fetched Nov 12, 2026